Skip to content

DISCLAIMER: This article is a SPONSORED Press Release and does not constitute Finbold's editorial content. Crypto assets/products involve significant risks. Do not invest unless you are prepared to lose your entire investment. For a full disclaimer, please click here.

Even Small Investors Can Make $50,000 This Cycle With These 3 Cryptos, The Last One is Better Than XRP

Press Releases

This bull run yielded high gains for investors after Bitcoin rushed past $64,000 overnight after the Fed cut rates. As the altcoins continue to trend higher and higher, Injective (INJ), and AAVE stand out as top buys which still have room for bullish gains even after locking in huge gains this week. 

Meanwhile, DTX Exchange (DTX) has surpassed XRP potential as the crypto awaits another legal battle with the U.S. Securities and Exchange Commission next month. As the demand soars for bullish cryptos with promising long-term prospects, the DTX token stands in line with Injective (INJ), and AAVE for the next round of bullish rebound. 

$200 Breakout Rally Imminent For AAVE Amid High Whale Action 

AAVE has secured a top spot in this bull run as whales rush to invest big for mega gains. The crypto has gained 6% value overnight after rising above the $155 resistance level and continues to maintain an upward trend with surging whale action. AAVE blockchain is also performing well, attracting diverse communities of traders to enjoy its robust growth. 

Major analysts have predicted a bullish scope for AAVE in the upcoming days as the technical charts suggest a rising RSI and improving moving averages, signaling a strong buying opportunity. If the AAVE price breaks past immediate resistance at $160, the potential price rally can trigger a continuation of the uptrend to the $200 price level. 

Injective (INJ) Kickstarts Bullish Rally to Conquer $25 Milestone

Injective (INJ) has also emerged as a star crypto during this cycle, with ground-breaking gains as BTC soars to new highs. Injective (INJ) has performed in a bullish pattern in recent weeks and its surging transactional volume points to a promising future for INJ tokens after 3% gains in the last 24 hours. 

Major crypto analyst Rekt Capital has also voiced bullish scope for Injective (INJ) after the crypto formed a falling wedge pattern that indicates rising whale activity and selling pressures. As Injective (INJ) kick starts a bullish run after the Fed’s rate cut decision, the next target of INJ price is at $25 which acts as a major traction for savvy investors. 

DTX Exchange (DTX) Labelled Top Buy After $2.7M Presale Run

DTX Exchange (DTX) holds top status in the traders’ community with its ground-breaking Defi model, leveraging hybrid features to merge the best features from centralized and decentralized models. Its advanced AI-powered trading platform with 1000x leverage is a power tool in the hands of global traders to maximize gains in assets from stocks, cryptos, forex, and bonds. 

This bullish cycle has pushed DTX Exchange (DTX) under the spotlight after raising a mind-blowing $2.7 million in batch 3 of the public presale, combined with the launch of its innovative and unique hybrid layer-1 blockchain. DTX platform upholds commitment to a decentralized web with KYC-free security and non-custodial wallets for personal asset optimization. 

Other than robust technical infrastructure and end-to-end solutions, DTX Exchange (DTX) is also a hub for community-driven initiatives with passive income strategies with liquidity pools and governance rights. DTX tokens can be bought at $0.06 in this presale stage as the price will rally unbounded once they hit the mainnet by the end of 2024. 

Key Takeaways

In a bullish altcoin market overflowing with big investments, AAVE, Injective (INJ), and DTX Exchange (DTX) are the moonshot cryptos with bigger gains. The star among all is the DTX Exchange is positioned to yield substantial gains and become a top contender, outperforming even XRP with its groundbreaking features. 

Learn more: 

Buy Presale

Visit DTX Website

Join The DTX Community

Disclaimer

This post is sponsored. Finbold neither endorses nor takes responsibility for the accuracy, quality, advertising, products, or other materials on this page. Readers are strongly encouraged to perform their own research before making any decisions regarding the company. Finbold will not be held accountable, either directly or indirectly, for any harm or loss that may stem from or be linked to the usage or reliance on any information, goods, or services mentioned on the page. If you encounter any issues, kindly report them to [email protected].

Sign Up

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

Already have an account? Sign In

Disclaimer: The information on this website is for general informational and educational purposes only and does not constitute financial, legal, tax, or investment advice. This site does not make any financial promotions, and all content is strictly informational. By using this site, you agree to our full disclaimer and terms of use. For more information, please read our complete Global Disclaimer.